 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Clinical, Review, Journal: .EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. (Pubmed Central) - Jan 20, 2022
EGFR mutations, such as T790M and C797S, are the most common mechanism of EGFR-TKI resistance. Here, we discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates.
- || TQB3804 / Sino Biopharm
Enrollment open, Metastases: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - Dec 15, 2019
P1, N=30, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Here, we discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates. Not yet recruiting --> Recruiting
- | TQB3804 / Sino Biopharm
New P1 trial, Metastases: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - Oct 15, 2019
P1, N=30, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.